Access Denied to FDA-Approved Alzheimer’s Treatments
A restrictive Centers for Medicare & Medicaid Services (CMS) policy, which only applies to those living with Alzheimer’s disease, is blocking access to FDA-approved treatments. CMS must reverse its unprecedented decision blocking Medicare coverage of current and future Alzheimer’s treatments.
A National Response to Alzheimer’s and Other Dementia
The bipartisan NAPA Reauthorization Act and the Alzheimer’s Accountability and Investment Act would build on the progress made over the last decade by continuing to promote rapid research and improve the delivery of clinical care and services for people living with Alzheimer’s and all other dementia.
A Path to Better Dementia Care
The bipartisan Comprehensive Care for Alzheimer’s Act would ask the Center for Medicare & Medicaid Innovation (CMMI) to test a different payment structure for dementia care management. This important bill has the potential to streamline today’s complicated health care maze for people living with dementia and their caregivers.
Our Nation’s Commitment to Alzheimer’s Research and Public Health Response
Congress must continue to invest in Alzheimer’s and dementia research at the National Institutes of Health (NIH), and fund the Building Our Largest Dementia (BOLD) Infrastructure for Alzheimer’s Act (P.L. 115-406) to strengthen the public health infrastructure across the country by implementing effective Alzheimer’s intervention focused on public health issues such as increasing early detection and diagnosis, reducing risk, and preventing avoidable hospitalizations.
Supporting Alzheimer’s Caregivers
An estimated 11 million Americans are providing unpaid care to someone living with dementia, and they need our support. While providing this assistance can be rewarding it's also quite challenging for the caregiver to sustain. The bipartisan Alzheimer’s Caregiver Support Act would provide much needed relief for our nation’s dementia caregivers.
Urge Your Representative to Support Access to Alzheimer’s Treatments
The Centers for Medicare & Medicaid Services (CMS) is still blocking coverage of FDA-approved treatments targeting amyloid for Alzheimer’s. Ask your U.S. representative to urge CMS to change this ...
Your Guide to Advocacy
Here’s everything you need to make the most of your year-round advocacy efforts to improve the lives of those impacted by Alzheimer’s and all other dementia. This guide will be updated throughout the year as our policy priorities are introduced and advanced.
Federal Priorities We Support
AIM is also a proud supporter of the following priorities in the 118th Congress.
Alzheimer's Accountability & Investment Act
Alzheimer's Treatments Letters to CMS & HHS
CAREERS Act of 2023
CMMI Letter on Dementia Care Management
Elder Justice Act Reauthorization
Elizabeth Dole HCBS for Veterans and Caregivers Act
FY24 Appropriations BOLD
FY24 Appropriations NIH Alzheimer's Research
FY24 Increasing Representation in Alzheimer's Clinical Trials
House Committee on Ways and Means, Health Subcommittee Hearing: Examining Policies that Inhibit Innovation and Patient Access
House Energy & Commerce Health Subcommittee: Preparing for and Responding to Future Public Health Security Threats
NAPA Reauthorization Act
Senate Aging Hearing: Supporting Communities of Care
Senate Finance Hearing: Improving Health Care Access in Rural Communities
Senate HELP Workforce Shortage Hearing
Senate HELP Committee: Workforce Shortage RFI Response
Senate VA Hearing: Strengthening Methods of Recruitment and Retention for VA’s Workforce
Be a Champion in the Fight to End Alzheimer’s
Our voices are stronger together. Help AIM advance legislation to improve the lives of people impacted by Alzheimer’s and all other dementia.
- Share your story with elected officials
- Engage on social media
- Write a letter to the editor